Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 6/2008

01.08.2008 | ORIGINAL PAPER

Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?

verfasst von: Emin Önder, Ümit Tural, Mehmet Gökbakan

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

The aim of this study was to compare efficacy of fluoxetine alone and co-administration of gabapentin and fluoxetine in patients with obsessive compulsive disorder (OCD).

Methods

Forty outpatients with a DSM-IV diagnosis of OCD were randomized to open label treatment, 20 of whom were treated with fluoxetine alone and the remaining 20 with fluoxetine plus gabapentin during 8 weeks. The severity was assessed by Yale-Brown Obsessive Compulsive Scale (Y-BOCS) and Clinical Global Impression (CGI).

Results

Final CGI-I and Y-BOCS scores were not significantly different in both groups. However, in repeated measures ANOVA, compared to fluoxetine group, we found significantly a better improvement in the fluoxetine plus gabapentin group at week 2 by means of YBOCS and CGI-I scores. Comparisons on weeks 4, 6 and 8 revealed no statistical differences between the groups. There was no significant difference of adverse effects between two groups.

Conclusions

Adding gabapentin to fluoxetine in the treatment of OCD seems to shorten the time to onset of fluoxetine’s anti-obsessive effect without a significant increase in adverse effects. In order to accelerate the clinical response, co-administration of fluoxetine and gabapentin may be a preferable strategy. On the other hand, further controlled studies are needed to support this finding.
Literatur
1.
Zurück zum Zitat Baxter LR (2001) Functional imaging of brain systems mediating obsessive-compulsive disorder. In: Charney DS, Nestler EJ, Bunny BS (eds) Neurobiology of mental illness. Oxford University Press, New York, pp 534–547 Baxter LR (2001) Functional imaging of brain systems mediating obsessive-compulsive disorder. In: Charney DS, Nestler EJ, Bunny BS (eds) Neurobiology of mental illness. Oxford University Press, New York, pp 534–547
2.
Zurück zum Zitat Brown JP, Gee NS (1998) Cloning and deletion mutagenesis of the α2δ calcium channel subunit from porcine cerebral cortex. J Biol Chem 273:25458–25465PubMedCrossRef Brown JP, Gee NS (1998) Cloning and deletion mutagenesis of the α2δ calcium channel subunit from porcine cerebral cortex. J Biol Chem 273:25458–25465PubMedCrossRef
3.
Zurück zum Zitat Chouinard G, Beauclair L, Bélanger MC (1998) Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders (Letter). Can J Psychiatry 43:305PubMed Chouinard G, Beauclair L, Bélanger MC (1998) Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders (Letter). Can J Psychiatry 43:305PubMed
4.
Zurück zum Zitat Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL (1998) Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder (Letter). J Clin Psychiatry 59:480–481PubMed Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL (1998) Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder (Letter). J Clin Psychiatry 59:480–481PubMed
5.
Zurück zum Zitat Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL (1998) Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry 59:82PubMed Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL (1998) Valproate monotherapy in an SRI-intolerant OCD patient. J Clin Psychiatry 59:82PubMed
6.
Zurück zum Zitat Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon D, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424–428PubMedCrossRef Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon D, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424–428PubMedCrossRef
7.
Zurück zum Zitat Çilli AS, Telcioğlu M, Aşkın R, Kaya N, Bodur S, Kucur R (2004) 12 month prevalence of obsessive-compulsive disorder in Konya, Turkey. Compr Psychiatry 45:367–374CrossRef Çilli AS, Telcioğlu M, Aşkın R, Kaya N, Bodur S, Kucur R (2004) 12 month prevalence of obsessive-compulsive disorder in Konya, Turkey. Compr Psychiatry 45:367–374CrossRef
8.
Zurück zum Zitat Çorapçıoğlu A, Aydemir Ö, Yıldız M, Danacı AE, Köroğlu E (1999) DSM-IV Eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçe’ye uyarlanması güvenirlik çalışması. (Adaptation to Turkish and reliability of Structured Clinical Interview for DSM-IV, Axis I disorders). İlaç ve Tedavi Dergisi 12:233–236 [Turkish] Çorapçıoğlu A, Aydemir Ö, Yıldız M, Danacı AE, Köroğlu E (1999) DSM-IV Eksen I bozuklukları için yapılandırılmış klinik görüşmenin Türkçe’ye uyarlanması güvenirlik çalışması. (Adaptation to Turkish and reliability of Structured Clinical Interview for DSM-IV, Axis I disorders). İlaç ve Tedavi Dergisi 12:233–236 [Turkish]
9.
Zurück zum Zitat Deltito JA (1994) Valproate pretreatment for the difficult-to-treat patient with OCD (Letter). J Clin Psychiatry 55:500PubMed Deltito JA (1994) Valproate pretreatment for the difficult-to-treat patient with OCD (Letter). J Clin Psychiatry 55:500PubMed
10.
Zurück zum Zitat De-Paris F, Busnello JV, Salgeuiro JB, Quevedo J, Izguierdo I, Kapczincki F (2000) The anticonvulsant compund gabapentin possesses anxiolytic but not amnesic effects in rats. Behav Pharmacol 11:169–173PubMed De-Paris F, Busnello JV, Salgeuiro JB, Quevedo J, Izguierdo I, Kapczincki F (2000) The anticonvulsant compund gabapentin possesses anxiolytic but not amnesic effects in rats. Behav Pharmacol 11:169–173PubMed
11.
Zurück zum Zitat De-Paris F, Sant’Anna MK, Vianna MRM, Barichello T, Busnello J (2003) Effects of gabapentin on anxiety induced by simulated public speaking. J Psychopharmacol 17:184–188PubMedCrossRef De-Paris F, Sant’Anna MK, Vianna MRM, Barichello T, Busnello J (2003) Effects of gabapentin on anxiety induced by simulated public speaking. J Psychopharmacol 17:184–188PubMedCrossRef
12.
Zurück zum Zitat Doğan O, Gülmez H, Ketenoğlu C, Kılıçkap Z, Özbek H, Akyüz G (1995) Ruhsal bozuklukların epidemiyolojisi [Epidemiology of psychiatric disorders]. Dilek Matbaası, Sivas, pp 50–52 [Turkish] Doğan O, Gülmez H, Ketenoğlu C, Kılıçkap Z, Özbek H, Akyüz G (1995) Ruhsal bozuklukların epidemiyolojisi [Epidemiology of psychiatric disorders]. Dilek Matbaası, Sivas, pp 50–52 [Turkish]
13.
Zurück zum Zitat Erol N, Kılıç C, Ulusoy M Keçeci M, Şimşek Z (1997) Türkiye Ruh Sağlığı Profili [Mental health profile of Turkey main report. Ministry of Health Publications]. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü, Ankara [Turkish] Erol N, Kılıç C, Ulusoy M Keçeci M, Şimşek Z (1997) Türkiye Ruh Sağlığı Profili [Mental health profile of Turkey main report. Ministry of Health Publications]. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü, Ankara [Turkish]
14.
Zurück zum Zitat First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV clinical version (SCID-I/CV). American Psychiatric Press, Washington, DC First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured clinical interview for DSM-IV clinical version (SCID-I/CV). American Psychiatric Press, Washington, DC
15.
Zurück zum Zitat Gee NS, Brown JP, Dissanayeke VUK, Offord J, Thurlow R, Woodruff GN (1996) The novel anticonvulsant drug gabapentin (neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 271:5768–5776PubMedCrossRef Gee NS, Brown JP, Dissanayeke VUK, Offord J, Thurlow R, Woodruff GN (1996) The novel anticonvulsant drug gabapentin (neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 271:5768–5776PubMedCrossRef
16.
Zurück zum Zitat Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown obsessive-compulsive scale I: development, use, and reliability. Arch Gen Psychiatry 46:1006–1111PubMed Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989) The Yale-Brown obsessive-compulsive scale I: development, use, and reliability. Arch Gen Psychiatry 46:1006–1111PubMed
17.
Zurück zum Zitat Guy W (1976) Early clinical drug evaluation until assessment manual for psychopharmacology. Publication ADM 76–338. US Department of Health, Education and Welfare, Washington, DC Guy W (1976) Early clinical drug evaluation until assessment manual for psychopharmacology. Publication ADM 76–338. US Department of Health, Education and Welfare, Washington, DC
18.
Zurück zum Zitat Honmou O, Oyelese AA, Kocsis JD (1995) The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 692:273–277PubMedCrossRef Honmou O, Oyelese AA, Kocsis JD (1995) The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis. Brain Res 692:273–277PubMedCrossRef
19.
Zurück zum Zitat Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N (2000) Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 61:528–529PubMedCrossRef Iwata Y, Kotani Y, Hoshino R, Takei N, Iyo M, Mori N (2000) Carbamazepine augmentation of clomipramine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychiatry 61:528–529PubMedCrossRef
21.
Zurück zum Zitat Jenike MA, Brotman AW (1984) The EEG in obsessive-compulsive disorder. J Clin Psychiatry 45:122–124PubMed Jenike MA, Brotman AW (1984) The EEG in obsessive-compulsive disorder. J Clin Psychiatry 45:122–124PubMed
22.
Zurück zum Zitat Johnson MR, Lydiard RB (1995) The neurobiology of anxiety disorders. Psychiatr Clin North Am 18:681–725PubMed Johnson MR, Lydiard RB (1995) The neurobiology of anxiety disorders. Psychiatr Clin North Am 18:681–725PubMed
23.
Zurück zum Zitat Karamustafalıoğlu OK, Üçışık AM, Ulusoy M, Erkmen H (1993) Yale-Brown Obsesyon Kompülsiyon Derecelendirme Ölçeğinin geçerlik ve güvenirlik çalışması [Validity and reliability study of Yale-Brown Obsession-Compulsion Scale]. Poster presented at 29th Congress of National Psychiatry Procedings book, 1993, p 86 [Turkish] Karamustafalıoğlu OK, Üçışık AM, Ulusoy M, Erkmen H (1993) Yale-Brown Obsesyon Kompülsiyon Derecelendirme Ölçeğinin geçerlik ve güvenirlik çalışması [Validity and reliability study of Yale-Brown Obsession-Compulsion Scale]. Poster presented at 29th Congress of National Psychiatry Procedings book, 1993, p 86 [Turkish]
24.
Zurück zum Zitat Kırpınar İ, Çayköylü A, Kuloğlu M (1994) Erzurum’da ruh sağlığı birimlerine ulaşım yolları [pathways to psychiatric units in Erzurum]. Turk Psikiyatri Derg 5:175–181 [Turkish] Kırpınar İ, Çayköylü A, Kuloğlu M (1994) Erzurum’da ruh sağlığı birimlerine ulaşım yolları [pathways to psychiatric units in Erzurum]. Turk Psikiyatri Derg 5:175–181 [Turkish]
25.
Zurück zum Zitat Kumar TC, Khanna S (2000) Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 34:527–528PubMedCrossRef Kumar TC, Khanna S (2000) Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry 34:527–528PubMedCrossRef
26.
Zurück zum Zitat Magistretti PJ, Pellerin L, Rothman DL, Shulman RG (1999) Energy on demand. Science 283:496–497PubMedCrossRef Magistretti PJ, Pellerin L, Rothman DL, Shulman RG (1999) Energy on demand. Science 283:496–497PubMedCrossRef
27.
Zurück zum Zitat McGrath MJ, Campbell KM, Parks CR, Burton FH (2000) Glutamatergic drugs exacerbate symptomatic behavior in transgenic model of comorbid Tourette’s syndrome and obsessive compulsive disorder. Brain Res 877:23–30PubMedCrossRef McGrath MJ, Campbell KM, Parks CR, Burton FH (2000) Glutamatergic drugs exacerbate symptomatic behavior in transgenic model of comorbid Tourette’s syndrome and obsessive compulsive disorder. Brain Res 877:23–30PubMedCrossRef
28.
Zurück zum Zitat Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348PubMedCrossRef Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM (1999) Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348PubMedCrossRef
29.
Zurück zum Zitat Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467–71PubMedCrossRef Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T (2000) Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467–71PubMedCrossRef
30.
Zurück zum Zitat Pollack MH, Matthews J, Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders (letter). Am J Psychiatry 155:992–993PubMed Pollack MH, Matthews J, Scott EL (1998) Gabapentin as a potential treatment for anxiety disorders (letter). Am J Psychiatry 155:992–993PubMed
31.
Zurück zum Zitat Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD,Stewart CM, Moore GJ (2000) Decrease incaudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096–1103PubMedCrossRef Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD,Stewart CM, Moore GJ (2000) Decrease incaudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39:1096–1103PubMedCrossRef
32.
Zurück zum Zitat Schruers K, Koning K, Luermans J, Haack MJ, Griez E (2005) Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 111:261–271PubMedCrossRef Schruers K, Koning K, Luermans J, Haack MJ, Griez E (2005) Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 111:261–271PubMedCrossRef
33.
Zurück zum Zitat Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN (1996) The antiepileptic agent gabapentin (Neurontin) posesses anxiolytic-like and antinociceptive action that are reversed by D-serine. Psychopharmacology 127:1–9PubMedCrossRef Singh L, Field MJ, Ferris P, Hunter JC, Oles RJ, Williams RG, Woodruff GN (1996) The antiepileptic agent gabapentin (Neurontin) posesses anxiolytic-like and antinociceptive action that are reversed by D-serine. Psychopharmacology 127:1–9PubMedCrossRef
34.
Zurück zum Zitat Suman-Chauhan N, Webdale L, Hill DR, Hunter JC, Oles RJ, Williams RG, Woodruff GN (1993) Characterisation of [3H] gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 244:293–301PubMedCrossRef Suman-Chauhan N, Webdale L, Hill DR, Hunter JC, Oles RJ, Williams RG, Woodruff GN (1993) Characterisation of [3H] gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 244:293–301PubMedCrossRef
35.
Zurück zum Zitat Van Ameringen M, Mancini C, Patterson B, Bennett M (2006) Topiramate augmentation in treatment resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 23:1–5PubMedCrossRef Van Ameringen M, Mancini C, Patterson B, Bennett M (2006) Topiramate augmentation in treatment resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 23:1–5PubMedCrossRef
36.
Zurück zum Zitat Zohar J, Fineberg N (2001) Practical pharmacotherapy. In: Fineberg N, Marazitti D, Stein D (eds) Obsessive-compulsive disorder: a practical guide. Martin Dunitz, London, pp 103–117 Zohar J, Fineberg N (2001) Practical pharmacotherapy. In: Fineberg N, Marazitti D, Stein D (eds) Obsessive-compulsive disorder: a practical guide. Martin Dunitz, London, pp 103–117
Metadaten
Titel
Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
verfasst von
Emin Önder
Ümit Tural
Mehmet Gökbakan
Publikationsdatum
01.08.2008
Verlag
D. Steinkopff-Verlag
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 6/2008
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-007-0798-z

Weitere Artikel der Ausgabe 6/2008

European Archives of Psychiatry and Clinical Neuroscience 6/2008 Zur Ausgabe

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

29.05.2024 Hörstörungen Nachrichten

Hört jemand im Alter schlecht, nimmt das Hirn- und Hippocampusvolumen besonders schnell ab, was auch mit einem beschleunigten kognitiven Abbau einhergeht. Und diese Prozesse scheinen sich unabhängig von der Amyloidablagerung zu ereignen.

So wirken verschiedene Alkoholika auf den Blutdruck

23.05.2024 Störungen durch Alkohol Nachrichten

Je mehr Alkohol Menschen pro Woche trinken, desto mehr steigt ihr Blutdruck, legen Daten aus Dänemark nahe. Ob es dabei auch auf die Art des Alkohols ankommt, wurde ebenfalls untersucht.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.